Literature DB >> 27868138

PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma.

Roland Schneiderbauer1, Malessa Schneiderbauer, Wolfgang Wick, Alexander H Enk, Holger A Haenssle, Jessica C Hassel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27868138     DOI： 10.2340/00015555-2548

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   4.437


× No keyword cloud information.
  10 in total

Review 1.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Alexandra M Haugh; John C Probasco; Douglas B Johnson
Journal:  Expert Opin Drug Saf       Date:  2020-03-11       Impact factor: 4.250

Review 2.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

Review 3.  Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

Authors:  Nizar M Tannir; Sumanta K Pal; Michael B Atkins
Journal:  Oncologist       Date:  2018-02-27

4.  Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma.

Authors:  Jonathan J D Baird-Gunning; Dinushi Weerasinghe; Matthew Silsby; Yash Gawarikar; Matteo S Carlino; Jessica L Smith; Steve Vucic
Journal:  Neurohospitalist       Date:  2018-05-27

5.  Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy.

Authors:  Saskia Bolz; Thivyah Ramakrishnan; Michael Fleischer; Elisabeth Livingstone; Benjamin Stolte; Andreas Thimm; Kathrin Kizina; Selma Ugurel; Christoph Kleinschnitz; Martin Glas; Lisa Zimmer; Tim Hagenacker
Journal:  eNeurologicalSci       Date:  2021-02-01

6.  Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies.

Authors:  Shohei Watanabe; Kazuki Yoshizumi; Sayaka Moriguchi; Tomoki Higashiyama; Yoshiki Negi; Koji Mikami; Takashi Kimura
Journal:  eNeurologicalSci       Date:  2021-12-03

Review 7.  Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature.

Authors:  Víctor Albarrán; Jesús Chamorro; Diana Isabel Rosero; Cristina Saavedra; Ainara Soria; Alfredo Carrato; Pablo Gajate
Journal:  Front Pharmacol       Date:  2022-02-14       Impact factor: 5.810

Review 8.  Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.

Authors:  Noelia Vilariño; Jordi Bruna; Foteini Kalofonou; Garifallia G Anastopoulou; Andreas A Argyriou
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

9.  Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report.

Authors:  Wenhui Liu; Bo Chen; Yiping Liu; Zhiying Luo; Bao Sun; Fang Ma
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.810

Review 10.  Immune Checkpoint Inhibitors and Neurotoxicity.

Authors:  Zhiyi Zhao; Chunlin Zhang; Lian Zhou; Pan Dong; Lei Shi
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.